At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST
3.55
+0.67
+23.26%
盘后3.60
+0.05+1.41%
19:59 EST
High3.66Low2.95Vol2.86M
Open2.95D1 Closing2.88Amplitude24.65%
Mkt Cap197.67MTradable Cap175.93MTotal Shares55.68M
T/O9.83MT/O Rate5.77%Tradable Shares49.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares
Reuters  ·  2025-12-30
Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares
BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study
Reuters  ·  2025-12-15
BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study
Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug
Reuters  ·  2025-12-15
Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients With Ataxia-Telangiectasia
THOMSON REUTERS  ·  2025-12-15
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients With Ataxia-Telangiectasia
Quince Therapeutics - Expects Topline Results in Q1 2026
THOMSON REUTERS  ·  2025-12-15
Quince Therapeutics - Expects Topline Results in Q1 2026
Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders
Reuters  ·  2025-12-11
Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders
Quince Therapeutics to Present at Piper Sandler Healthcare Conference
Reuters  ·  2025-11-24
Quince Therapeutics to Present at Piper Sandler Healthcare Conference
Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX)
TIPRANKS  ·  2025-11-14
Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX)
Quince Therapeutics announces positive iDSMB review for eDSP in Phase 3 study
TIPRANKS  ·  2025-11-11
Quince Therapeutics announces positive iDSMB review for eDSP in Phase 3 study
Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia
Reuters  ·  2025-11-11
Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia
Quince Therapeutics - No Safety Concerns Identified, Study to Continue Unmodified
THOMSON REUTERS  ·  2025-11-11
Quince Therapeutics - No Safety Concerns Identified, Study to Continue Unmodified
Quince Therapeutics - Topline Results From Study Expected in Q1 2026
THOMSON REUTERS  ·  2025-11-11
Quince Therapeutics - Topline Results From Study Expected in Q1 2026
Quince Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Reuters  ·  2025-11-07
Quince Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Quince Therapeutics Retracts Statement on NALL Study Results
Reuters  ·  2025-10-18
Quince Therapeutics Retracts Statement on NALL Study Results
Quince Therapeutics Announces Data from Phase 3 Trial on Walking Capacity in Children with AtaxiaTelangiectasia
Reuters  ·  2025-10-10
Quince Therapeutics Announces Data from Phase 3 Trial on Walking Capacity in Children with AtaxiaTelangiectasia
Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?
Simply Wall St.  ·  2025-10-07
Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?
Quince Therapeutics Secures Amendment to EIB Credit Facility, Reducing Cash Reserve Requirements and Adjusting Interest Terms for Early 2026
Reuters  ·  2025-09-27
Quince Therapeutics Secures Amendment to EIB Credit Facility, Reducing Cash Reserve Requirements and Adjusting Interest Terms for Early 2026
Quince Therapeutics Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile
Reuters  ·  2025-09-26
Quince Therapeutics Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile
Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026
Reuters  ·  2025-09-12
Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026
Quince Therapeutics Unveils Presentation on Innovative eDSP for Rare Disease Treatment and Phase 3 NEAT Clinical Trial Progress
Reuters  ·  2025-09-10
Quince Therapeutics Unveils Presentation on Innovative eDSP for Rare Disease Treatment and Phase 3 NEAT Clinical Trial Progress

Introduction

Company Name.
Quince Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--